Emcure currently has six biosimilars in the market, launched through its subsidiary Gennova Biopharmaceuticals. While it has developed these in-house so far, the drugmaker will also scout for partners with products not in their pipeline, for commercialisation in India as well as emerging markets.
Emcure doubling down on biosimilars pipeline: MD Satish Mehta
